Condition: Primary Sjögren's Syndrome · Sponsor: Beijing InnoCare Pharma Tech Co., Ltd.
This is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical study to evaluate the efficacy and safety of ICP-488 in participants with primary Sjögren's syndrome (pSjS).
This description comes directly from the study's public registry record.
Alexia Lu · 010-66609745 · CO_HGRAC@innocarepharma.com
Always discuss trial participation with your own doctor first.
| Peking | Beijing, Beijing Municipality, China | — |
| Chongqing Traditional Chinese Medicine Hospital | Chongqing, Chongqing Municipality, China | — |
| "Southwest Hospital, Army Medical University （The First Hospital Affiliated to Army Medical University）" | Chongqing, Chongqing Municipality, China | — |
| The First Affiliated Hospital of Xiamen University | Xiamen, Fujian, China | — |
| Sun Yat-sen Memorial Hospital, Sun Yat-sen University | Guangzhou, Guangdong, China | — |
| The Third Affiliated Hospital of Sun Yat-sen University | Guangzhou, Guangdong, China | — |
| The First Affiliated Hospital of Guangxi Medical University | Nanning, Guangxi, China | — |
| The Second Hospital of Hebei Medical University | Shijiazhuang, Hebei, China | — |
| Xiangya Hospital of Central South University | Changsha, Hunan, China | — |
| Zhuzhou Central Hospital | Zhuzhou, Hunan, China | — |
| "Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School" | Nanjin, Jiangsu, China | — |
| The Second Affiliated Hospital of Soochow University | Suzhou, Jiangsu, China | — |
+ 10 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07727486